Ayalew Tefferi, MD¹, Aref Al-Kali, MD¹, Kebede H. Begna, MD², Mrinal M Patnaik, MBBS¹, Terra L. Lasho, PhD^1*, Xiaolin Wang, ScD^3*, Ying Wan, PhD^4* and Curtis A. Hanson, MD⁵

¹Division of Hematology, Mayo Clinic, Rochester, MN
²Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN
³Geron Corporation, Menlo Park, CA
⁴Janssen Research & Development, Raritan, NJ
⁵Division of Hematopathology, Mayo Clinic, Rochester, MN

Srdan Verstovsek, MD¹, Ruben A. Mesa², Lynda M Foltz, MD³, Vikas Gupta, MD, MRCP, MRCPath⁴, John O. Mascarenhas, MD, MS⁵, Ellen K. Ritchie, MD⁶, Ronald Hoffman, M.D.⁷, Richard T. Silver, MD⁸, Marina Kremyanskaya, MD PhD⁹, Olga Pozdnyakova, MD^10*, Robert P. Hasserjian, MD¹¹, Elizabeth Trehu, MD¹², Mohamed E Salama, M.D.¹³, Hagop M Kantarjian, MD¹ and Jason Gotlib, MD¹⁴

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²Mayo Clinic, Scottsdale, AZ
³Hematology, St. Paul's Hospital and the University of British Columbia, Vancouver, BC, Canada
⁴Princess Margaret Hospital, Toronto, ON, Canada
⁵Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY
⁶Division of Hematology / Oncology, Weill Cornell Medical College, New York, NY
⁷Tish Cancer Institute, Mount Sinai School of Medicine, New York, NY
⁸Weill Cornell Medical College, New York, NY
⁹The Myeloproliferative Research Consortium, The myeloproliferative Program, Tisch Cancer Institute, Icahn Schoool of Medicine at Mount Sinai, New York, NY
¹⁰Pathology, Brigham and Womens Hospital, Boston, MA
¹¹Department of Pathology, Massachusetts General Hospital, Boston, MA
¹²Promedior, Inc., Lexington, MA
¹³Department of Pathology, University of Utah, Salt Lake City, UT
¹⁴School of Medicine/ Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA

Elisabeth Oppliger Leibundgut, PharmD¹, Monika Haubitz, PhD^1*, Bart Burington, PhD^2*, Oliver G. Ottmann, MD^3*, Gary Spitzer, MD⁴, Olatoyosi Odenike, MD⁵, Michael A McDevitt, MD, PhD⁶, Alexander Roeth, MD⁷, David S. Snyder, MD⁸ and Gabriela M. Baerlocher, MD¹

¹Department of Hematology and Clinical Research, University Hospital and University of Bern, Bern, Switzerland
²Geron Corporation, Menlo Park, CA
³Department of Haematology, Cardiff University, Cardiff, United Kingdom
⁴Upstate Oncology Associates, Greenville
⁵University of Chicago Medical Center, Chicago, IL
⁶Johns Hopkins University School of Medicine, Baltimore, MD
⁷Department of Hematology, University Hospital Essen, Essen, Germany
⁸Gehr Family Center for Leukemia Research, City of Hope National Medical Center, Duarte, CA

Alessandro M. Vannucchi¹, Ruben A. Mesa², Francisco Cervantes³, Ritam Prasad⁴, Janos Jakucs^5*, Anna Elinder^6*, Christian Recher, MD PhD⁷, Peter A. te Boekhorst^8*, Steven Knapper⁹, Tim Somervaille¹⁰, James P. Dean¹¹, Tanya Granston^11*, Adam Mead^12* and Claire N. Harrison¹³

¹University of Florence, Florence, Italy
²Mayo Clinic, Scottsdale, AZ
³Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
⁴Royal Hobart Hospital, Hobart, Australia
⁵Békés Megyei Pándy Kálmán Kórház, Gyula, Hungary
⁶North Shore Hospital, Takapuna, New Zealand
⁷Institut Universitaire du Cancer, Toulouse, France
⁸Erasmus University Medical Center, Rotterdam, Netherlands
⁹Cardiff University, Cardiff, United Kingdom
¹⁰The Christie NHS Foundation Trust, Manchester, United Kingdom
¹¹CTI BioPharma Corp., Seattle, WA
¹²Oxford University Hospitals, Oxford, United Kingdom
¹³Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom

Claire N. Harrison¹, Alessandro M. Vannucchi, MD², Jean-Jacques Kiladjian³, Haifa Kathrin Al-Ali, MD^4*, Heinz Gisslinger, MD⁵, Laurent Knoops, MD, PhD^6*, Francisco Cervantes⁷, Mark M. Jones, MD^8*, Kang Sun, PhD^8*, Laurence Descamps, PhD^9*, Viktoriya Stalbovskaya, PhD^10*, Prashanth Gopalakrishna, MBBS, MRCS^10* and Tiziano Barbui, MD^11*

¹Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
²University of Florence, Florence, Italy
³Hôpital Saint-Louis and Paris Diderot University, Paris, France
⁴University of Leipzig, Leipzig, Germany
⁵Medical University of Vienna, Vienna, Austria
⁶Cliniques Universitaires Saint-Luc and de Duve Institute, Université catholique de Louvain, Brussels, Belgium
⁷Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
⁸Incyte Corporation, Wilmington, DE
⁹Novartis Pharma S.A.S, Rueil-Malmaison, France
¹⁰Novartis Pharma AG, Basel, Switzerland
¹¹Hospital Papa Giovanni XXIII and Research Foundation, Bergamo, Italy

Lucia Masarova, MD^1*, Srdan Verstovsek, MD¹, Keyur P. Patel, MD, PhD^2*, Kate J Newberry, PhD^3*, Jorge E. Cortes, MD⁴, Gautam Borthakur, MD¹, Marina Konopleva, MD, PhD⁵, Zeev Estrov, MD⁶ and Hagop M. Kantarjian, MD¹

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
³Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
⁴Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
⁵Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
⁶Department of Leukemia, The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX